Printer Friendly

FIRST HUMAN CLINICAL TRIAL BEGINS FOR CYTOTHERAPEUTICS' CERECRIB IMPLANT IN SWITZERLAND

 PROVIDENCE, R.I., June 18 /PRNewswire/ -- CytoTherapeutics, Inc. (NASDAQ: CTII) today announced that the first human clinical trial for its CereCRIB(tm) implant has begun. The trial is being conducted by Dr. Patrick Aebischer, a founding scientist at CytoTherapeutics, at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, Switzerland.
 Dr. Aebischer, an inventor of the encapsulation technology licensed to the company, is currently professor of Surgery and director of Surgical Research at the CHUV and professor of Biomaterials at Brown University in Providence.
 The initial study of the CereCRIB implant is designed to determine the safety of the implant procedure, as well as the survival of encapsulated, non-human cells that have been transplanted into humans. Volunteers participating in the study are seriously ill patients. Results are expected approximately year-end and will be presented in an appropriate scientific forum.
 CytoTherapeutics is a leader in the development and commercial application of implantable delivery systems for biologically active and gene therapy products for the treatment of central nervous system (CNS) diseases and other chronic disorders. The company's CNS products in development include its CereCRIB implant for the treatment of severe, chronic pain, and its NeuroCRIB(tm) implant for the treatment of Parkinson's disease. CytoTherapeutics is also developing its EndoCRIB(tm) implant for the treatment of Type I diabetes.
 -0- 6/18/93
 /CONTACT: Thomas G. Wiggans, chief operating officer, 401-272-3310, ext. 2152, or Elizabeth Razee, communications coordinator, 401-272-3310, ext. 2132, both of CytoTherapeutics/
 (CTII)


CO: CytoTherapeutics, Inc. ST: Rhode Island IN: MTC SU:

DJ -- NE007 -- 3630 06/18/93 14:27 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 18, 1993
Words:259
Previous Article:AMERICAN MUNICIPAL INCOME PORTFOLIO OFFERS 5,000,000 SHARES; MINNESOTA MUNICIPAL INCOME PORTFOLIO OFFERS 3,600,000 SHARES
Next Article:NEW ENGLAND REALTY ASSOCIATES, LIMITED PARTNERSHIP ANNOUNCES EXTENSION OF ODD-LOT REPURCHASE
Topics:


Related Articles
STRYKER'S BONE-GROWTH DEVICE APPROVED FOR CLINICAL STUDIES
CELLULAR TRANSPLANTS, INC. CHOOSES NEW NAME, CYTOTHERAPEUTICS, INC.
THOMAS WIGGANS NAMED CHIEF OPERATING OFFICER OF CYTOTHERAPEUTICS
CYTOTHERAPEUTICS AND DRS. WEISS AND REYNOLDS TO INVESTIGATE USES OF NEURAL STEM CELLS TO TREAT NEURODEGENERATIVE DISORDERS
CYTOTHERAPEUTICS AND GENETIC THERAPY TO INVESTIGATE ENCAPSULATION OF FACTOR IX TO TREAT HEMOPHILIA B
DR. MARJORIE CHRISTIE APPOINTED DIRECTOR OF REGULATORY SCIENCES AT CYTOTHERAPEUTICS
DONALD R. CONKLIN JOINS BOARD AT CYTOTHERAPEUTICS
CYTOTHERAPEUTICS ELECTS DANIEL GEFFKEN CHIEF FINANCIAL OFFICER
CYTOTHERAPEUTICS REPORTS THIRD QUARTER RESULTS
RESEARCHERS DEMONSTRATE CYTOTHERAPEUTICS' DELIVERY SYSTEM FOR NERVE GROWTH FACTOR PRESERVES NEURONS AFFECTED IN ALZHEIMER'S DISEASE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters